Sector: Health Care
Director information for WATERS CORP (data for year 2026)
| Name | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| Christopher A. Kuebler | Independent Director | 72 | ["Over 30 years of commercial execution experience in the pharmaceutical service industry","Expertise in overseeing global operations expansion, strategic growth and shareholder value creation initiatives","Oversight of financial accounting and business strategy","Spearheaded Covance’s spin-off from Corning Pharmaceutical Services","Chairman at Covance Inc. (2005) and Chairman and CEO (1994-2004)","Nearly 20 years in the pharmaceutical industry at Abbott Laboratories, Squibb, Inc., and the Monsanto Company","BS in Biology from Florida State University"] | ["Compensation","Science and Technology"] | 2026 |
| Claire M. Fraser, Ph.D. | Director | 70 | ["internationally recognized scientist","strong background in genomics, infectious diseases and molecular diagnostics","leader of two large research institutes for over 30 years","director of several biotechnology companies and non-profit organizations","experience working with a multinational company","enterprise risk management","director of Becton, Dickinson and Company"] | ["Science and Technology"] | 2026 |
| Dan Brennan | Independent Director | 60 | ["Extensive insights and experience in the medical device industry","Expertise in business development strategies, capital management and financial reporting","EVP and CFO at Boston Scientific","Certified Public Accountant"] | ["Audit & Finance"] | 2026 |
| Flemming Ørnskov, M.D., M.P.H. | Chair of the Board | 68 | ["Operational and medical expertise in the healthcare sector","Extensive international and strategic planning experience","CEO of Galderma (2019 – present)","CEO and Board member of Shire plc (2013 – 2019)","Chief Marketing Officer at Bayer AG (2010 – 2012)","Global President at Bausch & Lomb, Inc. (2008 – 2010)","Various roles at Merck & Co. Inc. and Novartis AG","Named one of the Top 100 Best-Performing CEOs in the World by Harvard Business Review"] | ["Nominating and Corporate Governance","Compensation"] | 2026 |
| Heather Knight | Independent Director | 54 | ["Significant healthcare industry expertise from nearly 30 years of experience","Global experience driving commercial execution across the MedTech industry","Successful track record of building high-performance culture with a focus on human capital management and talent development"] | ["Nominating and Corporate Governance"] | 2026 |
| Linda Baddour | Independent Director | 67 | ["Significant accounting, finance and health care industry expertise","Extensive experience as a senior financial executive across healthcare, life sciences, and pharmaceutical services and banking companies","Oversaw the financial strategy of PRA Health Sciences","Deep familiarity with all aspects of life science industry financial reporting, accounting, compliance and risk management","Retired Certified Public Accountant","EVP and CFO at PRA Health Sciences (2007 – 2018)","CFO and Accounting Officer at Pharmaceutical Product Development, Inc. (2002 – 2007)","Chief Accounting Officer at Pharmaceutical Product Development, Inc. (1997 – 2007)","Corporate Controller at Pharmaceutical Product Development, Inc. (1995 – 1997)","Controller at Cooperative Bank for Savings Inc. (1980 – 1995)","BA and MBA, University of North Carolina at Wilmington"] | ["Audit & Finance"] | 2026 |
| Mark Vergnano | Independent Director | 68 | ["valuable leadership insights developed through executive roles at global chemical companies","extensive operational experience and a proven track record of driving business transformation, financial growth and value creation","Global operations leadership experience, including manufacturing","deep understanding of sales and marketing in the chemical and industrial sector","track record of successful leadership over global science companies through transformative periods of significant growth","experience in government affairs and public policy while at DuPont"] | ["Compensation","Nominating and Corporate Governance"] | 2026 |
| Pearl S. Huang, Ph.D. | Independent Director | 68 | ["Deep scientific knowledge","International and operational experience in the pharmaceutical sector","Leadership in the biopharmaceutical industry for more than 30 years","Successful oversight of drug and therapy research and development","Oversaw a Novartis-backed biopharmaceutical startup","Recognized as an innovative science leader"] | ["Science and Technology (Chair)","Nominating and Corporate Governance"] | 2026 |
| Richard Fearon | Independent Director | 70 | ["seasoned strategic, planning, and operational leader","extensive international business, corporate finance and accounting, business development, M&A and investor relations expertise","experienced global operations leader","insights into complex financial compliance, accounting, information systems and internal audit processes"] | ["Audit & Finance"] | 2026 |
| Udit Batra, Ph.D. | President and CEO | 55 | ["More than two decades of operational leadership experience","Senior executive level with multi-billion-dollar global organizations","Guiding Waters’ commercial execution and expanding product portfolio adoption","Successfully oversaw financial and operational strategies with Merck KGaA","CEO of MilliporeSigma at Merck KGaA (2014 – 2020)","Various leadership roles at Novartis International AG (2006 – 2011)","Global Brand Director at Johnson & Johnson (2004 – 2005)","Senior Engagement Manager at McKinsey & Company (2001 – 2004)","Research Fellow at Merck & Co., Inc. (1996 – 2001)"] | [] | 2026 |
| Wei Jiang | Independent Director | 62 | ["More than 25 years of experience in the pharmaceutical and medical device industries","Deep operational leadership experience in Asia-Pacific region's pharma and biopharma markets","Expertise in overseeing key business growth initiatives and partnerships","Knowledge on evolving complexities of Asia-Pacific region operations"] | ["Science and Technology"] | 2026 |
